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COMMENTARY
Combination therapy for hypertension
Introduction
Hypertension affects more than one tenth of the adult popu-
lation in Hong Kong.1 In fact, using the latest recommended
cut-off points for systolic blood pressure of 140 mm Hg
and diastolic blood pressure of 90 mm Hg,2 the prevalence
of hypertension in Hong Kong adults is close to 20%. The
apparent increase in the prevalence of hypertension in
recent years is largely due to increased recognition of iso-
lated systolic hypertension and its associated risks.
Ideal blood pressure
The Hypertension Optimal Treatment (HOT) study failed
to show any significant differences in outcomes for target
diastolic blood pressures of less than 80, 85, or 90 mm Hg,
but did at least show that a target of 80 mm Hg is safe.3 More
than one drug is frequently needed to decrease the blood
pressure to this level, however. For high-risk groups such as
patients with diabetes or nephropathy, the target blood pres-
sure has been reduced to a lower level. In the UK Prospect-
ive Diabetes Study (UKPDS), tight blood pressure control,
rather than glycaemic control, was responsible for reducing
the incidence of macrovascular complications.4 Patients with
diabetes in the HOT study also benefited from lower target
blood pressures despite small differences in the achieved
blood pressure values among the randomised groups.3
In the Heart Outcomes Prevention Evaluation (HOPE)
study, patients treated with an angiotensin converting
enzyme inhibitor (ACEI) had a lower cardiovascular event
rate even if they were normotensive.5 It is generally believed
that ACEIs have a protective effect beyond blood pressure
reduction. An alternative possibility is that lowering the
blood pressure by a small amount for people at high cardio-
vascular risk is beneficial, even for normotensive people.
This leads to the new hypothesis that instead of treating
patients whose blood pressure exceeds a certain level, blood
pressure should be lowered for all people who are at risk
from strokes and heart attacks.6
Blood pressure control in reality
While the prevalence of hypertension in the community is
alarming, more disturbing is how badly blood pressure is
controlled in patients who are known to be hypertensive.
Given the relationship between raised blood pressure and
stroke risk, good control of blood pressure is crucial for stroke
prevention.7 In Hong Kong, as in the US, blood pressure is
effectively controlled in no more than 50% of patients.2,8
Why is blood pressure so poorly controlled? The
reasons include disease severity, patient factors, doctor
factors, and drug-related factors. As hypertension is usually
asymptomatic and complications such as stroke, heart
attack, and heart and kidney failures usually appear only
after time, patients are unlikely to present with character-
istic symptoms. Treatment does not bring immediately
obvious benefits to patients and involves inconvenience,
medication side-effects, and expense, all of which in-
fluence compliance. Treatment failure may also be due to
suboptimal drug therapy, with low doses, inappropriate
or wrong dose schedules, or suboptimal use of therapeutic
options (monotherapy or combination therapy).
Synergism
Currently available antihypertensive drugs are similar in
their overall effectiveness in lowering blood pressure. The
response to different agents varies from person to person,
however.9,10 To effectively control blood pressure, the clini-
cian may increase the drug dose or change to another drug.
There are non-empirical ways of predicting response,
such as using renin measurements11 or the ‘Cambridge
ABCD rule’.9 Plasma renin can be measured,11 usually in a
research clinic setting—as a simple rule of thumb, younger
and older patients can be assumed to have high or low renin
levels, respectively.9 The high renin form of hypertension is
more responsive to drugs that block the renin angiotensin
system, whereas the low renin form is more responsive to
diuretics and calcium channel blockers. Nevertheless, these
strategies only serve to select the best monotherapy for a
patient. A survey of the utilisation of antihypertensive drugs
in the Hypertension Clinic at Queen Mary Hospital showed
that 60% of patients were taking more than one antihyper-
tensive agent.12 Rather than combining drugs on an empir-
ical basis, there are rational combinations of drugs with
different and complementary modes of action that should
be considered. Examples of recognised combinations include
diuretics and β-blockers,13 diuretics and ACEIs,14 diuretics
and angiotensin receptor blockers (ARBs),15 and ACEIs and
calcium channel blockers.16
The combination of a diuretic and a blocker of the renin
angiotensin system such as an ACEI or an ARB is synergistic
in terms of efficacy. In terms of side-effects, combination
therapy is also better. For example, diuretics stimulate the
renin angiotensin system and can cause hypokalaemia in
up to 50% of patients.17 This is reduced by the addition of an
ACEI or ARB.14,15 In general, the enhanced antihypertensive
efficacy of synergistic combinations allows lower doses of
ingredient drugs with fewer dose-dependent adverse effects.
Evidence-based therapy
Most of the early hypertension trials employed diuretics
in combination with another agent, usually a potassium-
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sparing diuretic or a β-blocker.18,19 Thiazide diuretics were
rarely given on their own because of the risk of hypokalae-
mia or because of the improved blood pressure–lowering
effect when given in combination with other drugs. Diuret-
ics have been well-tested for stroke prevention and are
recommended in all hypertension treatment guidelines.2,20
A recent landmark trial, the Perindopril Protection
against Recurrent Stroke Study (PROGRESS), showed that
strokes are prevented more often in patients taking a
combination of indapamide and perindopril than in those
taking perindopril alone.21 The unique factorial design of
the study allowed statistical comparison of the combination
of indapamide and perindopril with perindopril alone.
The superior results of the combination were shown by the
lower blood pressure values achieved. Another recent land-
mark trial, the Losartan Intervention For Endpoint reduc-
tion in hypertension (LIFE) study, showed that losartan
prevented cardiovascular events, mostly strokes, better than
atenolol.22 Less than one tenth of patients in this trial were
receiving monotherapy. Hydrochlorothiazide was the
add-on medication. Although these trials purported to show
that ACEIs and ARBs prevent strokes, in clinical practice a
diuretic should also be included in the regimen, as in these
trials.
Improved compliance and economy
Better efficacy and a lower incidence of side-effects with
effective combination therapy should enhance compliance.
Compliance decreases with the number of tablets taken daily,
however.23 Therefore, if more than one antihypertensive is
used, there may be a place for fixed-dose combinations,
which have the advantage of improved compliance, fewer
tablets for the patient to take, and less room for dosing
error. Compliance with other non-antihypertensive drugs
may also improve, especially for elderly people who are
taking multiple medications. In some countries, fixed-dose
combinations are cheaper than prescribing the two drugs
separately, both in terms of acquisition costs and patients’
drug bills. For the pharmacy, there are fewer drug items to
dispense, therefore enhancing efficiency and accuracy.
Fixed-dose combinations do have some disadvantages,
however, in that there is less scope for titration, and ascer-
taining the ingredient drug responsible for certain side-
effects is problematic. Also, there are some patients for
whom monotherapy is sufficient.
Conclusions
The advantages of combination therapy for hypertension in-
clude better blood pressure control through the utilisation of
synergistic combinations, decreased incidence of side-effects,
improved patient compliance, and increased economy and
efficiency. Many clinical trials of hypertension have con-
centrated on comparison between specific agents. The time
has come to test combinations of antihypertensive drugs.
The use of logical, empirical combinations is now supported
by accumulated evidence from clinical trials. New guide-
lines on the management of hypertension are likely to
emphasise tight blood pressure control, especially for
those patient with a high cardiovascular risk who are taking
combinations of antihypertensive drugs.
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